14,700 Shares in Altimmune, Inc. (NASDAQ:ALT) Acquired by Bayesian Capital Management LP

Bayesian Capital Management LP purchased a new stake in shares of Altimmune, Inc. (NASDAQ:ALT) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 14,700 shares of the company’s stock, valued at approximately $106,000.

Several other large investors have also recently made changes to their positions in ALT. Barclays PLC grew its holdings in shares of Altimmune by 1.1% in the fourth quarter. Barclays PLC now owns 157,528 shares of the company’s stock worth $1,135,000 after purchasing an additional 1,787 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Altimmune by 2.0% during the fourth quarter. JPMorgan Chase & Co. now owns 102,940 shares of the company’s stock worth $742,000 after purchasing an additional 2,028 shares during the period. B. Riley Wealth Advisors Inc. grew its stake in shares of Altimmune by 12.9% in the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock worth $144,000 after purchasing an additional 2,687 shares during the last quarter. MetLife Investment Management LLC increased its holdings in Altimmune by 7.0% during the 4th quarter. MetLife Investment Management LLC now owns 44,474 shares of the company’s stock valued at $321,000 after purchasing an additional 2,897 shares during the period. Finally, Teacher Retirement System of Texas raised its position in Altimmune by 19.2% during the 4th quarter. Teacher Retirement System of Texas now owns 21,205 shares of the company’s stock valued at $153,000 after purchasing an additional 3,423 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Trading Up 8.3 %

Shares of Altimmune stock opened at $5.81 on Friday. Altimmune, Inc. has a 12 month low of $3.55 and a 12 month high of $11.16. The stock has a 50 day moving average of $5.09 and a 200 day moving average of $6.61. The firm has a market cap of $447.14 million, a PE ratio of -3.75 and a beta of 1.13.

Altimmune (NASDAQ:ALT) last posted its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. As a group, equities research analysts forecast that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Transactions at Altimmune

In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were purchased at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the purchase, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ALT. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research report on Thursday, April 3rd. William Blair restated a “market perform” rating on shares of Altimmune in a report on Friday, March 14th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $20.83.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.